key: cord-1030436-cjogyhgc
authors: Sanz, Cristina; Faúndez, Annabel; García, Anna; Rodríguez, Marta; Jaramillo, Anny Coromoto; Pereira, Arturo
title: Perfil clínico y motivo de transfusión de sangre en pacientes infectados por SARS-CoV-2
date: 2021-07-29
journal: Med Clin (Barc)
DOI: 10.1016/j.medcli.2021.07.008
sha: 9a3f51a3a2ae9ca871c6455d0186d7026809b79e
doc_id: 1030436
cord_uid: cjogyhgc

Background. There are few data on the clinical characteristics of COVID-19 patients who require blood transfusion. We aimed to investigate the clinical characteristics and indication for transfusion in COVID-19 patients seen during the epidemic’s first wave. Material and Methods. Cross-sectional study that included all consecutive COVID-19 patients admitted to the Hospital Clínic of Barcelona, Spain, from mid-March to mid-May 2020. Results: A total of 80 patients received 354 RBC units, 116 plasma units, and 48 platelet units. Median age was 71 years (IQR: 62-76), and 59 (74%) were males. In total, 138 of the 261 transfusion episodes that involved RBCs (59%) were related to spontaneous (n=94) or procedure-related (n=44) bleeding. Spontaneous bleeding was more frequent in the retroperitoneal space and the gastrointestinal apparatus. Tracheostomy with endotracheal intubation, surgical interventions, and cannulation of femoral vessels were the main procedures behind non-spontaneous bleeding. Most patients (91%) were on anticoagulants, mostly intermediate- or full-dose heparin. Conclusion: anticoagulation-related bleeding was a leading cause of blood transfusion in COVID-19 patients during the epidemic’s first-wave. Introducción: Las características de los pacientes con COVID-19 transfundidos son poco conocidas. Nuestro objetivo fue investigar el perfil clínico y el motivo de la transfusión en los pacientes con COVID-19 vistos durante la primera ola de la epidemia. Material y métodos: Estudio transversal que incluyó a todos los pacientes con COVID-19 transfundidos en el Hospital Clínic de Barcelona entre marzo y mayo de 2020. Resultados: Ochenta pacientes recibieron 354 unidades de hematíes, 116 de plasma y 48 de plaquetas. La edad mediana fue de 71 años y 59 (74%) eran hombres. En total, 138 de los 261 episodios de transfusión de hematíes (59%) estaban relacionados con hemorragia espontánea (n = 94; principalmente retroperitoneal y gastrointestinal) o con procedimientos invasivos (n = 44; principalmente traqueostomía, cirugía, y canulación de vasos femorales). El 91% de los pacientes recibían tratamiento anticoagulante el día de la transfusión o los dos días previos, sobre todo heparina a dosis intermedia o completa. Conclusión: el sangrado relacionado con la anticoagulación fue el motivo principal de transfusión en los pacientes con COVID-19.

Introducción: Las características de los pacientes con COVID-19 transfundidos son poco conocidas. Nuestro objetivo fue investigar el perfil clínico y el motivo de la transfusión en los pacientes con COVID-19 vistos durante la primera ola de la epidemia.

Material y métodos: Estudio transversal que incluyó a todos los pacientes con COVID-19 transfundidos en el Hospital Clínic de Barcelona entre marzo y mayo de 2020.

Resultados: Ochenta pacientes recibieron 354 unidades de hematíes, 116 de plasma y 48 de plaquetas. La edad mediana fue de 71 años y 59 (74%) eran hombres. En total, 138 de los 261 episodios de transfusión de hematíes (59%) estaban relacionados con hemorragia espontánea (n = 94; principalmente retroperitoneal y gastrointestinal) o con procedimientos invasivos (n = 44; principalmente traqueostomía, cirugía, y canulación de vasos femorales). El 91% de los pacientes recibían tratamiento anticoagulante el día de la transfusión o los dos días previos, sobre todo heparina a dosis intermedia o completa.

Conclusión: el sangrado relacionado con la anticoagulación fue el motivo principal de transfusión en los pacientes con COVID-19.

Palabras clave: Transfusión de sangre. Hemorragia. Anticoagulantes. COVID-19.

The ongoing pandemic of COVID-19 is severely challenging healthcare systems all around the world. With regard to blood transfusion, studies have documented a decrease in blood collection because of fear of infection and social distancing policies, and a concomitant reduction in transfusion driven by the brutal change in the case-mix of admitted patients [1] [2] [3] . Notably, little has been published about the clinical characteristics of COVID-19 patients who require blood transfusion.

The present study aimed to describe blood usage by COVID-19 patients during the first epidemic wave, with a particular emphasis on the clinical features of transfused patients and the indication for transfusion.

For this cross-sectional study, we reviewed the blood bank and electronic clinical records of 80 consecutive patients diagnosed with COVID 19, who required red blood cells (RBC) transfusion at the Hospital Clínic of Barcelona over 60 days, from mid-March to mid-May 2020. The period on study ranged from the date the first patient was transfused to the date when a week had elapsed without new transfusions to COVID-19 patients. COVID-19 was confirmed by at least two PCR test in nasopharyngeal swaps. Categorical data were described as frequencies and percentages, and continuous variables were summarized as the median and interquartile range (IQR). Written informed consent was obtained from each patient, and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in a priori approval by the Ethics Committee of our institution (code: HCB.2020.0541). 

The present study shows that bleeding, mostly related to anticoagulants, was the main indication for RBC transfusion in patients with COVID-19. Few previous reports are available to contrast this finding. In a small series from South Chorea at the beginning of the epidemics, only two of nine transfused patients were on anticoagulants [3] . In the report by Pagano et al. [4] , on 13 COVID-19 patients transfused in Seattle between late February and early April, indications consisted of pre-existing comorbidities and anaemia of chronic disease, without any specific mention to haemorrhage or anticoagulants. Later studies found that RBC transfusion was more prevalent in patients on anticoagulants but did not provide clinical details about transfusion indications [5] .

The poor prognostic significance of hypercoagulability markers in COVID-19, and the beneficial effect of heparin treatment, often guided by serum D-dimer levels, were progressively recognized over the first months of the SARS-CoV-2 epidemic [6, 7] . Therefore, it is not rare that early reports did not find bleeding associated with anticoagulants as an indication for blood transfusion in COVID-19 patients.

Changes in the indications for blood transfusion throughout the epidemic, and differences in the crowding-out of the usual inpatient case-mix by the massive admission of COVID-19 patients, preclude any sound comparison of blood usage among hospitals. Variability among centres in the use of ECMO can also contribute to differences in blood usage because ECMO has been associated with increased need for RBC transfusion [8] . Despite this difficulty, our results are consistent with previous studies reporting a reduced overall demand for transfusion during the SARS-CoV-2 epidemic [5, [8] [9] . We relied on patient stays instead of admissions as a yardstick to measure transfusion intensity in COVID-19 patients because it was more appropriate to the bounded period on study.

We were astonished by the high prevalence of retroperitoneal hematoma as a cause Page 7 of 14 J o u r n a l P r e -p r o o f for RBC transfusion in our patients, a complication that was often difficult to diagnose, as revealed by the medical records. In a series of 89 patients with spontaneous retroperitoneal hematoma, 85% were on anticoagulant or antiplatelet medications, and pain referred to the abdomen, hip or flank was the leading complaint [10] .

In our series, haemorrhage was often protracted and difficult to control, and transfusion support extended for several days. Not rarely, haemorrhage recurred when the patient was restarted on anticoagulants, and it was not unusual for bleeding from an anatomical location to be followed by and overlapped with bleeding from a different location.

Our study has some limitations. First, results derived from a single centre during the learning curve of how to manage the severe complications of COVID-19, so that they may not apply to other centres or situations. Second, we did not investigate whether transfusion was a surrogate for worse prognosis in COVID-19, as we did not compare transfused and non-¡transfused patients. Third, the study was focused on transfused patients and did not allow to draw any quantitative conclusion on the risk of bleeding associated with the use of anticoagulants in COVID-19, which would require a different study design. Third, Despite the above limitations, our results point at anticoagulation-related bleeding as a leading cause for blood transfusion in COVID-19 patients.

Bleeding, mostly related to the use of anticoagulants, was the main indication for RBC transfusion in patients with COVID-19. 

Effects of the COVID-19 pandemic on supply and use of blood for transfusion

Blood donations and transfusions during the COVID-19 pandemic in Spain: impact according to autonomous communities and hospitals

Blood and blood product use during COVID-19 infection

Blood use and transfusion needs at a large health care system in Washington state during the SARS-CoV-2 pandemic

Transfusion demand in COVID-19 patients from the Korean population: a nationwide study in South Korea

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Risk assessment of venous thromboembolism and bleeding in COVID-19 patients

Blood component use in critical care in patients with COVID-19 infection: a

Blood transfusion utilization in hospitalized COVID-19 patients

Spontaneous retroperitoneal hematoma: etiology, characteristics, management, and outcome

All authors have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.